MP81-06 RADIOMIC FEATURES OF PROSTATE CANCER PATIENTS (GLEASON GRADE GROUP = 2) SHOW DIFFERENCES BETWEEN AFRICAN AMERICAN AND CAUCASIAN POPULATIONS ON BI-PARAMETRIC MRI: PRELIMINARY FINDINGS (2020)

You have accessJournal of UrologyProstate Cancer: Detection & Screening VIII (MP81)1 Apr 2020MP81-06 RADIOMIC FEATURES OF PROSTATE CANCER PATIENTS (GLEASON GRADE GROUP = 2) SHOW DIFFERENCES BETWEEN AFRICAN AMERICAN AND CAUCASIAN POPULATIONS ON BI-PARAMETRIC MRI: PRELIMINARY FINDINGS Rakesh Shiradkar*, Amr Mahran, Shivam Sharma, Britt Conroy, Sree Harsha Tirumani, Lee Ponsky, and Anant Madabhushi Rakesh Shiradkar*Rakesh Shiradkar* More articles by this author , Amr MahranAmr Mahran More articles by this author , Shivam SharmaShivam Sharma More articles by this author , Britt ConroyBritt Conroy More articles by this author , Sree Harsha TirumaniSree Harsha Tirumani More articles by this author , Lee PonskyLee Ponsky More articles by this author , and Anant MadabhushiAnant Madabhushi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000973.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recent studies tend to suggest that African American (AA) men harbor more aggressive prostate cancer (PCa) than their Caucasian (CA) counterparts which may likely be on account of biological factors. These differences may also manifest on magnetic resonance imaging (MRI) and we seek to evaluate if radiomic features can quantify these differences which could potentially aid in development of population specific risk stratification models. METHODS: In this retrospective, anonymized, IRB approved study, N = 41 PCa patients were identified with a biopsy Gleason Grade Group (GGG) = 2, which presented an almost equal distribution of AA (N=19) and CA (N=22) populations. All patients underwent 3T multi-parametric MRI prior to 12-core ultrasound guided biopsy and definitive therapy. An experienced radiologist delineated PCa regions on interest (ROI) on bi-parametric MRI (T2-weighted MRI (T2W) and apparent diffusion coefficient (ADC) maps). Radiomic features were derived from the ROIs on T2W and ADC. Wilcoxon rank-sum test was used to identify radiomic features with statistically significant differences (p<0.05) between AA and CA patients. Routinely used clinical parameters including prostate specific antigen (PSA), prostate imaging reporting and data system (PIRADS-v2), GGG, prostate and tumor volume are also compared across the two population groups. RESULTS: Radiomic features including first order statistics of ADC values, Haralick and Gabor features derived from ADC maps showed statistically significant differences (p<0.05) between AA and CA patients. These features quantify the underlying spatial heterogeneity on imaging. In comparison, none of the clinical variables (including mean ADC) except PI-RADSv2 scores showed significant differences between the population groups. CONCLUSIONS: Radiomic features quantifying heterogeneity within the tumor on ADC maps were observed to show significant differences between AA and CA patients controlled for Gleason Grade (GGG = 2) PCa from biopsy. Population specific differences may need to be considered while developing risk stratification models using radiomic features. Source of Funding: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers 1U24CA199374-01, R01CA202752-01A1R01CA208236-01A1. R01 CA216579-01A1R01 CA220581-01A11U01 CA239055-01 National Center for Research Resources under award number 1 C06 RR12463-01. VA Merit Review Award IBX004121. A from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service. The DoD Breast Cancer Research Program Breakthrough Level 1 Award W81XWH-19-1-0668. The DOD Prostate Cancer Idea Development Award (W81XWH-15-1-0558). The DOD Lung Cancer Investigator-Initiated Translational Research Award (W81XWH-18-1-0440). The DOD Peer Reviewed Cancer Research Program (W81XWH-16-1-0329). The Ohio Third Frontier Technology Validation Fund. The Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering and The Clinical and Translational Science Award Program (CTSA) at Case Western Reserve University. DoD Prostate Cancer Research Program Idea Development Award W81XWH-18-1-0524 © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1238-e1238 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rakesh Shiradkar* More articles by this author Amr Mahran More articles by this author Shivam Sharma More articles by this author Britt Conroy More articles by this author Sree Harsha Tirumani More articles by this author Lee Ponsky More articles by this author Anant Madabhushi More articles by this author Expand All Advertisement PDF downloadLoading ...